Patients were randomized to receive either Rebetol (800-1,200 mg/day based on weight) plus peginterferon alfa-2b (100 or 150 µg/week based on weight) or Rebetol (800- 1,200 mg/day based on weight) plus interferon alfa-2b (3 MIU TIW).